Osemitamab |
MSB-018; TST-001 |
Phase 3 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms |
Details
|
IBI-343 |
IBI-343 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms |
Details
|
LM-302 |
TPX-4589; LM-302 |
Phase 3 Clinical |
Eli Lilly Trading (Shanghai) Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms |
Details
|
SHR-A-1904 |
SHR-A-1904; SHR-A1904 |
Phase 3 Clinical |
Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Pancreatic Neoplasms |
Details
|
M-108 |
M108; M-108 |
Phase 3 Clinical |
FutureGen Biopharm (Beijing) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms |
Details
|
CMG-901 |
CMG-901; CMG901; AZD-0901; AZD0901 |
Phase 3 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma |
Details
|
ASKB-589 |
ASKB-589 |
Phase 3 Clinical |
Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
KD-182 |
KD-182 |
Phase 2 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Stomach Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) |
AB-011 |
Phase 2 Clinical |
Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
CLDN18.2-TAC T cells Therapy |
CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells |
Phase 2 Clinical |
Triumvira Immunologics Inc |
Solid tumours; Stomach Neoplasms; Neoplasm Metastasis |
Details
|
HBM-7022 |
HBM-7022; AZD-5863 |
Phase 2 Clinical |
Harbour Biomed |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms |
Details
|
XNW-27011 |
XNW-27011 |
Phase 2 Clinical |
Suzhou Sinovent Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
IMC-002(Suzhou Immunofoco) |
IMC-002 |
Phase 2 Clinical |
Suzhou Immunofoco Biotechnology Co Ltd |
Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma |
Details
|
PM-1032 |
PM1032; PM-1032 |
Phase 2 Clinical |
Biotheus Inc, Shanghai Genechem Co Ltd |
Neoplasms |
Details
|
PT-886 |
PT-886; PT886 |
Phase 2 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
ATG-022 |
ATG-022 |
Phase 2 Clinical |
Antengene Corporation Co Ltd |
Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis |
Details
|
QLS-31905 |
QLS-31905 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
SOT-102 |
SOT-102; SOT102; SO-N102 |
Phase 2 Clinical |
Sotio Biotech AG |
Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
Q-1802 |
Q-1802 |
Phase 2 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms |
Details
|
Recombinant humanized monoclonal antibody MIL93(Mabworks) |
MIL-93 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Neoplasms |
Details
|
RC-118 |
RC-118; YH005 ADC |
Phase 2 Clinical |
RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd |
Solid tumours; Neoplasm Metastasis |
Details
|
Satricabtagene autoleucel |
CT041; CT-041 |
Phase 2 Clinical |
CARsgen Therapeutics Holdings Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
SPX-101 (Sparx Therapeutics) |
KY-71113; SX-001; KY71113; SPX-101 |
Phase 1 Clinical |
Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc |
Solid tumours; Stomach Neoplasms |
Details
|
IM-92 |
IM-92 |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
KD-496 |
KD-496(4th); KD-496 |
Phase 1 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms |
Details
|
Gresonitamab |
AMG-910 |
Phase 1 Clinical |
Amgen Inc |
Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma |
Details
|
AZD-6422 |
AZD6422; AZD-6422 |
Phase 1 Clinical |
Astrazeneca Plc |
Gastrointestinal Neoplasms |
Details
|
68Ga-PMD22(Peking Union Medical College Hospital) |
|
Phase 1 Clinical |
Peking Union Medical College Hospital |
Gastrointestinal Neoplasms |
Details
|
AK-132 |
AK132; AK-132 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
TQB-2103 |
TQB2103; TQB-2103 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms |
Details
|
BIO-008 |
BIO-008 |
Phase 1 Clinical |
Shijiazhuang Yiling Pharmaceutical Co Ltd |
Solid tumours |
Details
|
BA-1301 |
BA-1301; BA1301 |
Phase 1 Clinical |
|
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
LB-1904 |
LB-1904 |
Phase 1 Clinical |
|
Stomach Neoplasms |
Details
|
CT-048 |
CT-048; KJ-C1807; KJ-C-1807 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
ASP-2138 |
ASP-2138 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc, Xencor Inc |
Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
LB-4330 |
Bis-2; LB-4330 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours |
Details
|
HEC-016 |
HEC-016 |
Phase 1 Clinical |
People Hospital Of Luohu,Shenzhen |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
PM-3023 |
PM-3023 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
RD-07 |
RD-07 |
Phase 1 Clinical |
Peking University |
Solid tumours |
Details
|
JS-107 |
JS-107; JS107 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Solid tumours; Pancreatic Neoplasms |
Details
|
TORL-2-307-ADC |
TORL-2-307-ADC |
Phase 1 Clinical |
Torl Biotherapeutics LLC |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
BC-008 |
BC-008 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical |
Solid tumours; Neoplasms |
Details
|
BC-007 (Dragonboat Biopharmaceutical) |
BC-007 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical |
Solid tumours; Neoplasms |
Details
|
DR-30303 |
DR30303 |
Phase 1 Clinical |
Zhejiang Doer Biologics Corp |
Solid tumours |
Details
|
SG-1906 |
SG-1906; SG1906 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
SKB-315 |
SKB-315; SKB315 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
BA-1105 |
BA-1105; BA1105 |
Phase 1 Clinical |
|
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
LY-011(Shanghai Longyao) |
LY-011 |
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
IBI-389 |
IBI-389 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
NBL-015 |
NBL-015 |
Phase 1 Clinical |
Shanghai Xinshi Biological Medicine Co Ltd |
Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
IBI-360 |
IBI-360 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
SYSA-1801 |
SYSA-1801; SYSA1801; CPO-102; EO-3021 |
Phase 1 Clinical |
Jushi Biopharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
Givastomig |
TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis |
Details
|
QL-1779 |
QL-1779; QL1779 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
LM-102 |
LM-102 |
Phase 1 Clinical |
LaNova Medicines Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
HBM-1029 |
HBM-1029; HBM1029 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
LCAR-C18S CAR-T cell therapy |
LB-1908; LCAR-C18S; LCAR-C-18-S |
Phase 1 Clinical |
|
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
CLDN18.2 UCAR-T cell therapy |
CLDN18.2 UCAR-T |
Clinical |
Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd |
Stomach Neoplasms |
Details
|
124I-18B10 |
124-I-18-B-10; 124I-18B10 |
Clinical |
Transcenta Holding Ltd, Beijing Cancer Hospital |
Gastrointestinal Neoplasms |
Details
|
89Zr-NY005 |
89Zr-NY005 |
Clinical |
Wuxi No 4 People'S Hospital |
Solid tumours |
Details
|
IBI-345 |
IBI-345 |
|
Innovent Biologics(Suzhou) Co Ltd |
|
Details
|
Osemitamab |
MSB-018; TST-001 |
Phase 3 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms |
Details
|
IBI-343 |
IBI-343 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms |
Details
|
LM-302 |
TPX-4589; LM-302 |
Phase 3 Clinical |
Eli Lilly Trading (Shanghai) Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms |
Details
|
SHR-A-1904 |
SHR-A-1904; SHR-A1904 |
Phase 3 Clinical |
Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Pancreatic Neoplasms |
Details
|
M-108 |
M108; M-108 |
Phase 3 Clinical |
FutureGen Biopharm (Beijing) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms |
Details
|
CMG-901 |
CMG-901; CMG901; AZD-0901; AZD0901 |
Phase 3 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma |
Details
|
ASKB-589 |
ASKB-589 |
Phase 3 Clinical |
Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
KD-182 |
KD-182 |
Phase 2 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Stomach Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) |
AB-011 |
Phase 2 Clinical |
Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
CLDN18.2-TAC T cells Therapy |
CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells |
Phase 2 Clinical |
Triumvira Immunologics Inc |
Solid tumours; Stomach Neoplasms; Neoplasm Metastasis |
Details
|
HBM-7022 |
HBM-7022; AZD-5863 |
Phase 2 Clinical |
Harbour Biomed |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms |
Details
|
XNW-27011 |
XNW-27011 |
Phase 2 Clinical |
Suzhou Sinovent Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
IMC-002(Suzhou Immunofoco) |
IMC-002 |
Phase 2 Clinical |
Suzhou Immunofoco Biotechnology Co Ltd |
Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma |
Details
|
PM-1032 |
PM1032; PM-1032 |
Phase 2 Clinical |
Biotheus Inc, Shanghai Genechem Co Ltd |
Neoplasms |
Details
|
PT-886 |
PT-886; PT886 |
Phase 2 Clinical |
Phanes Therapeutics Inc |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
ATG-022 |
ATG-022 |
Phase 2 Clinical |
Antengene Corporation Co Ltd |
Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis |
Details
|
QLS-31905 |
QLS-31905 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
SOT-102 |
SOT-102; SOT102; SO-N102 |
Phase 2 Clinical |
Sotio Biotech AG |
Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
Q-1802 |
Q-1802 |
Phase 2 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms |
Details
|
Recombinant humanized monoclonal antibody MIL93(Mabworks) |
MIL-93 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Neoplasms |
Details
|
RC-118 |
RC-118; YH005 ADC |
Phase 2 Clinical |
RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd |
Solid tumours; Neoplasm Metastasis |
Details
|
Satricabtagene autoleucel |
CT041; CT-041 |
Phase 2 Clinical |
CARsgen Therapeutics Holdings Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
SPX-101 (Sparx Therapeutics) |
KY-71113; SX-001; KY71113; SPX-101 |
Phase 1 Clinical |
Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc |
Solid tumours; Stomach Neoplasms |
Details
|
IM-92 |
IM-92 |
Phase 1 Clinical |
Beijing Immunochina Medical Science & Technology Co Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
KD-496 |
KD-496(4th); KD-496 |
Phase 1 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms |
Details
|
Gresonitamab |
AMG-910 |
Phase 1 Clinical |
Amgen Inc |
Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma |
Details
|
AZD-6422 |
AZD6422; AZD-6422 |
Phase 1 Clinical |
Astrazeneca Plc |
Gastrointestinal Neoplasms |
Details
|
68Ga-PMD22(Peking Union Medical College Hospital) |
|
Phase 1 Clinical |
Peking Union Medical College Hospital |
Gastrointestinal Neoplasms |
Details
|
AK-132 |
AK132; AK-132 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms |
Details
|
TQB-2103 |
TQB2103; TQB-2103 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms |
Details
|
BIO-008 |
BIO-008 |
Phase 1 Clinical |
Shijiazhuang Yiling Pharmaceutical Co Ltd |
Solid tumours |
Details
|
BA-1301 |
BA-1301; BA1301 |
Phase 1 Clinical |
|
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
LB-1904 |
LB-1904 |
Phase 1 Clinical |
|
Stomach Neoplasms |
Details
|
CT-048 |
CT-048; KJ-C1807; KJ-C-1807 |
Phase 1 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
ASP-2138 |
ASP-2138 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc, Xencor Inc |
Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
LB-4330 |
Bis-2; LB-4330 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours |
Details
|
HEC-016 |
HEC-016 |
Phase 1 Clinical |
People Hospital Of Luohu,Shenzhen |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
PM-3023 |
PM-3023 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
RD-07 |
RD-07 |
Phase 1 Clinical |
Peking University |
Solid tumours |
Details
|
JS-107 |
JS-107; JS107 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Solid tumours; Pancreatic Neoplasms |
Details
|
TORL-2-307-ADC |
TORL-2-307-ADC |
Phase 1 Clinical |
Torl Biotherapeutics LLC |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma |
Details
|
BC-008 |
BC-008 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical |
Solid tumours; Neoplasms |
Details
|
BC-007 (Dragonboat Biopharmaceutical) |
BC-007 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical |
Solid tumours; Neoplasms |
Details
|
DR-30303 |
DR30303 |
Phase 1 Clinical |
Zhejiang Doer Biologics Corp |
Solid tumours |
Details
|
SG-1906 |
SG-1906; SG1906 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
SKB-315 |
SKB-315; SKB315 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
BA-1105 |
BA-1105; BA1105 |
Phase 1 Clinical |
|
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
LY-011(Shanghai Longyao) |
LY-011 |
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
IBI-389 |
IBI-389 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
NBL-015 |
NBL-015 |
Phase 1 Clinical |
Shanghai Xinshi Biological Medicine Co Ltd |
Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms |
Details
|
IBI-360 |
IBI-360 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
SYSA-1801 |
SYSA-1801; SYSA1801; CPO-102; EO-3021 |
Phase 1 Clinical |
Jushi Biopharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
Givastomig |
TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis |
Details
|
QL-1779 |
QL-1779; QL1779 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
LM-102 |
LM-102 |
Phase 1 Clinical |
LaNova Medicines Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
HBM-1029 |
HBM-1029; HBM1029 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
LCAR-C18S CAR-T cell therapy |
LB-1908; LCAR-C18S; LCAR-C-18-S |
Phase 1 Clinical |
|
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms |
Details
|
CLDN18.2 UCAR-T cell therapy |
CLDN18.2 UCAR-T |
Clinical |
Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd |
Stomach Neoplasms |
Details
|
124I-18B10 |
124-I-18-B-10; 124I-18B10 |
Clinical |
Transcenta Holding Ltd, Beijing Cancer Hospital |
Gastrointestinal Neoplasms |
Details
|
89Zr-NY005 |
89Zr-NY005 |
Clinical |
Wuxi No 4 People'S Hospital |
Solid tumours |
Details
|
IBI-345 |
IBI-345 |
|
Innovent Biologics(Suzhou) Co Ltd |
|
Details
|